Developing a vaccine to prevent infections caused by Haemophilus influenzae
Official title: Haemophilus influenzae lipoprotein fusion vaccine and lipoprotein vaccine platform development
Funded at Rochester General Hospital (Ny) · NIH-11020285 · Data updated 2026-11-12
This study is working on a new vaccine to help protect kids and adults from respiratory infections caused by a germ called Nontypeable Haemophilus influenzae, and it’s testing how well this vaccine works in mice to see if it can keep people from getting sick.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rochester General Hospital (Ny) NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | November 18, 2024 |
| Project end | October 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $404,539 |
| NIH project number | 1R01AI187168-01 |
| Project ID | NIH-11020285 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children and adults who are at risk for NTHi infections, such as those with asthma or chronic respiratory conditions.
✕Less likely to help
Patients who do not have respiratory conditions or are not at risk for NTHi infections may not receive any benefit from this research.
What this research studies
This research focuses on creating a vaccine to protect against Nontypeable Haemophilus influenzae (NTHi), which is responsible for various respiratory infections in both children and adults. The approach involves testing lipidated proteins that enhance immune responses, specifically targeting the generation of antibodies and T-cell memory against NTHi. The study will utilize a mouse model to evaluate the effectiveness of these novel vaccine constructs in preventing infections in the respiratory tract. If successful, this vaccine could significantly reduce the incidence of serious respiratory infections caused by NTHi.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces respiratory infections caused by NTHi, improving health outcomes for affected patients.
How similar studies have gone: Previous research has shown promise in enhancing immune responses through lipidation of proteins, indicating potential success for this novel approach.
Where this research is happening
-
Rochester General Hospital (Ny)
Rochester, United States Active
Researchers
- Principal investigator: Pichichero, Michael E — Rochester General Hospital (Ny)
- Study coordinator: Pichichero, Michael E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.